The association of SOX2 expression with the progression of other several human cancer cells has been reported [63–65] but the role of SOX2 in these cancers remains controversial [66] as Yang et al. [67] reported that SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP2 via the PI3K/AKT/mechanistic target of the rapamycin pathway, while Yoon et al. [68] indicated that overexpression of SOX2 is associated with better overall survival in squamous cell lung cancer patients treated with adjuvant radiotherapy. This evidence concerns the gene SOX2 and cancer.